Sarepta shares up as FDA approves AMONDYS 45 for Duchenne Muscular Dystrophy
February 25 2021 - 2:27PM
Seeking Alpha
To read the full story on Seeking Alpha, click
here.
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2023 to Apr 2024